vs
博士伦（BLCO）与TechnipFMC plc（FTI）财务数据对比。点击上方公司名可切换其他公司
TechnipFMC plc的季度营收约是博士伦的1.8倍（$2.5B vs $1.4B），TechnipFMC plc净利率更高（9.6% vs -4.1%，领先13.8%），博士伦同比增速更快（9.8% vs 6.3%），TechnipFMC plc自由现金流更多（$359.1M vs $60.0M），过去两年博士伦的营收复合增速更高（13.1% vs 11.0%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
TechnipFMC是一家注册地位于英国的全球能源服务商，兼具法国与美国企业背景，核心业务为油气领域提供专业技术与服务支持。公司由美国FMC科技与法国Technip于2016年宣布合并，2017年正式完成组建，业务覆盖全球主要能源市场。
BLCO vs FTI — 直观对比
营收规模更大
FTI
是对方的1.8倍
$1.4B
营收增速更快
BLCO
高出3.4%
6.3%
净利率更高
FTI
高出13.8%
-4.1%
自由现金流更多
FTI
多$299.1M
$60.0M
两年增速更快
BLCO
近两年复合增速
11.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $2.5B |
| 净利润 | $-58.0M | $242.7M |
| 毛利率 | — | — |
| 营业利润率 | 8.0% | 12.6% |
| 净利率 | -4.1% | 9.6% |
| 营收同比 | 9.8% | 6.3% |
| 净利润同比 | -1833.3% | 8.0% |
| 每股收益（稀释后） | $-0.16 | $0.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCOFTI
| Q4 25 | $1.4B | $2.5B | ||
| Q3 25 | $1.3B | $2.6B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | $1.1B | $2.2B | ||
| Q4 24 | $1.3B | $2.4B | ||
| Q3 24 | $1.2B | $2.3B | ||
| Q2 24 | $1.2B | $2.3B | ||
| Q1 24 | $1.1B | $2.0B |
净利润BLCOFTI
| Q4 25 | $-58.0M | $242.7M | ||
| Q3 25 | $-28.0M | $309.7M | ||
| Q2 25 | $-62.0M | $269.5M | ||
| Q1 25 | $-212.0M | $142.0M | ||
| Q4 24 | $-3.0M | $224.7M | ||
| Q3 24 | $4.0M | $274.6M | ||
| Q2 24 | $-151.0M | $186.5M | ||
| Q1 24 | $-167.0M | $157.1M |
毛利率BLCOFTI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 23.1% | ||
| Q1 25 | — | 20.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 21.2% | ||
| Q1 24 | — | 16.4% |
营业利润率BLCOFTI
| Q4 25 | 8.0% | 12.6% | ||
| Q3 25 | 7.4% | 16.5% | ||
| Q2 25 | -0.9% | 15.9% | ||
| Q1 25 | -7.3% | 12.5% | ||
| Q4 24 | 6.8% | 11.3% | ||
| Q3 24 | 3.6% | 13.7% | ||
| Q2 24 | 2.1% | 13.3% | ||
| Q1 24 | 0.5% | 12.7% |
净利率BLCOFTI
| Q4 25 | -4.1% | 9.6% | ||
| Q3 25 | -2.2% | 11.7% | ||
| Q2 25 | -4.9% | 10.6% | ||
| Q1 25 | -18.6% | 6.4% | ||
| Q4 24 | -0.2% | 9.5% | ||
| Q3 24 | 0.3% | 11.7% | ||
| Q2 24 | -12.4% | 8.0% | ||
| Q1 24 | -15.2% | 7.7% |
每股收益（稀释后）BLCOFTI
| Q4 25 | $-0.16 | $0.58 | ||
| Q3 25 | $-0.08 | $0.75 | ||
| Q2 25 | $-0.18 | $0.64 | ||
| Q1 25 | $-0.60 | $0.33 | ||
| Q4 24 | $-0.00 | $0.51 | ||
| Q3 24 | $0.01 | $0.63 | ||
| Q2 24 | $-0.43 | $0.42 | ||
| Q1 24 | $-0.48 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $1.0B |
| 总债务越低越好 | $5.0B | $430.0M |
| 股东权益账面价值 | $6.4B | $3.4B |
| 总资产 | $14.0B | $10.1B |
| 负债/权益比越低杠杆越低 | 0.78× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资BLCOFTI
| Q4 25 | $383.0M | $1.0B | ||
| Q3 25 | $310.0M | $876.6M | ||
| Q2 25 | $266.0M | $950.0M | ||
| Q1 25 | $202.0M | $1.2B | ||
| Q4 24 | $305.0M | $1.2B | ||
| Q3 24 | $329.0M | — | ||
| Q2 24 | $285.0M | — | ||
| Q1 24 | $315.0M | — |
总债务BLCOFTI
| Q4 25 | $5.0B | $430.0M | ||
| Q3 25 | $5.0B | $438.0M | ||
| Q2 25 | $5.0B | $696.3M | ||
| Q1 25 | $4.8B | $904.9M | ||
| Q4 24 | $4.8B | $885.2M | ||
| Q3 24 | $4.6B | $966.7M | ||
| Q2 24 | $4.6B | $968.4M | ||
| Q1 24 | $4.6B | $1.0B |
股东权益BLCOFTI
| Q4 25 | $6.4B | $3.4B | ||
| Q3 25 | $6.4B | $3.3B | ||
| Q2 25 | $6.4B | $3.3B | ||
| Q1 25 | $6.4B | $3.1B | ||
| Q4 24 | $6.5B | $3.1B | ||
| Q3 24 | $6.6B | $3.3B | ||
| Q2 24 | $6.5B | $3.0B | ||
| Q1 24 | $6.7B | $3.0B |
总资产BLCOFTI
| Q4 25 | $14.0B | $10.1B | ||
| Q3 25 | $13.8B | $10.3B | ||
| Q2 25 | $13.8B | $10.1B | ||
| Q1 25 | $13.4B | $10.0B | ||
| Q4 24 | $13.5B | $9.9B | ||
| Q3 24 | $13.5B | $9.7B | ||
| Q2 24 | $13.3B | $9.2B | ||
| Q1 24 | $13.3B | $9.1B |
负债/权益比BLCOFTI
| Q4 25 | 0.78× | 0.13× | ||
| Q3 25 | 0.77× | 0.13× | ||
| Q2 25 | 0.77× | 0.21× | ||
| Q1 25 | 0.76× | 0.29× | ||
| Q4 24 | 0.74× | 0.29× | ||
| Q3 24 | 0.70× | 0.30× | ||
| Q2 24 | 0.71× | 0.33× | ||
| Q1 24 | 0.69× | 0.34× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $453.6M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $359.1M |
| 自由现金流率自由现金流/营收 | 4.3% | 14.3% |
| 资本支出强度资本支出/营收 | 5.4% | 3.8% |
| 现金转化率经营现金流/净利润 | — | 1.87× |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $1.4B |
8季度趋势，按日历期对齐
经营现金流BLCOFTI
| Q4 25 | $136.0M | $453.6M | ||
| Q3 25 | $137.0M | $525.1M | ||
| Q2 25 | $35.0M | $344.2M | ||
| Q1 25 | $-25.0M | $441.7M | ||
| Q4 24 | $22.0M | $578.9M | ||
| Q3 24 | $154.0M | $277.9M | ||
| Q2 24 | $15.0M | $230.9M | ||
| Q1 24 | $41.0M | $-126.7M |
自由现金流BLCOFTI
| Q4 25 | $60.0M | $359.1M | ||
| Q3 25 | $63.0M | $447.8M | ||
| Q2 25 | $-54.0M | $260.6M | ||
| Q1 25 | $-135.0M | $379.9M | ||
| Q4 24 | $-70.0M | $452.7M | ||
| Q3 24 | $94.0M | $225.3M | ||
| Q2 24 | $-57.0M | $180.1M | ||
| Q1 24 | $-26.0M | $-178.7M |
自由现金流率BLCOFTI
| Q4 25 | 4.3% | 14.3% | ||
| Q3 25 | 4.9% | 16.9% | ||
| Q2 25 | -4.2% | 10.3% | ||
| Q1 25 | -11.9% | 17.0% | ||
| Q4 24 | -5.5% | 19.1% | ||
| Q3 24 | 7.9% | 9.6% | ||
| Q2 24 | -4.7% | 7.7% | ||
| Q1 24 | -2.4% | -8.8% |
资本支出强度BLCOFTI
| Q4 25 | 5.4% | 3.8% | ||
| Q3 25 | 5.8% | 2.9% | ||
| Q2 25 | 7.0% | 3.3% | ||
| Q1 25 | 9.7% | 2.8% | ||
| Q4 24 | 7.2% | 5.3% | ||
| Q3 24 | 5.0% | 2.2% | ||
| Q2 24 | 5.9% | 2.2% | ||
| Q1 24 | 6.1% | 2.5% |
现金转化率BLCOFTI
| Q4 25 | — | 1.87× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.28× | ||
| Q1 25 | — | 3.11× | ||
| Q4 24 | — | 2.58× | ||
| Q3 24 | 38.50× | 1.01× | ||
| Q2 24 | — | 1.24× | ||
| Q1 24 | — | -0.81× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
FTI
| Services | $1.3B | 52% |
| Products | $1.1B | 44% |
| Other | $55.1M | 2% |
| Surface Technologies | $22.4M | 1% |
